Haemonetics reported quarterly EPS of $1.29, edging past the Zacks consensus estimate of $1.28 and up from $1.24 a year ago. The beat is modest, but it indicates slightly better-than-expected operating performance. The news is positive for the stock, though likely limited in broader market impact.
Haemonetics reported quarterly EPS of $1.29, edging past the Zacks consensus estimate of $1.28 and up from $1.24 a year ago. The beat is modest, but it indicates slightly better-than-expected operating performance. The news is positive for the stock, though likely limited in broader market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
